Linezolid or vancomycin surgical site infection prophylaxis LOVip

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504986-22-00

Enrollment

1160

Registered

2023-08-18

Start date

2024-09-30

Completion date

Unknown

Last updated

2025-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

surgical antibiotic prophylaxis

Brief summary

The primary objective of this study is to show the non-inferiority in terms of rate of d30 post-surgery SSIs in patients receiving linezolid 1200 mg as surgical antibiotic prophylaxis compared with patients receiving vancomycin 30 mg/kg.

Interventions

DRUGVANCOMYCIN

DRUGVANCOMYCINE SANDOZ 500 mg

DRUGpoudre pour solution à diluer pour perfusion ou pour solution buvable

DRUGVANCOMYCINE SANDOZ 250 mg

DRUGpoudre pour solution à diluer pour perfusion

DRUGVancomycine MIP 1000 mg

DRUGpoudre pour solution pour perfusion

DRUGVANCOMYCINE SANDOZ 125 mg

DRUGVANCOMYCINE VIATRIS 250 mg

DRUGVancomycine MIP 500 mg

DRUGVANCOMYCINE VIATRIS 1000 mg

DRUGVANCOMYCINE HIKMA 500 mg

DRUGPoudre pour solution à diluer pour perfusion

DRUGLinezolid Kabi 2 mg/ml solution for infusion

DRUGVANCOMYCINE SANDOZ 1 g

DRUGVANCOMYCINE VIATRIS 125 mg

DRUGVANCOMYCINE HIKMA 1000 mg

DRUGVANCOMYCINE VIATRIS 500 mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary objective of this study is to show the non-inferiority in terms of rate of d30 post-surgery SSIs in patients receiving linezolid 1200 mg as surgical antibiotic prophylaxis compared with patients receiving vancomycin 30 mg/kg.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026